

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Alectinib for untreated anaplastic lymphoma kinase
positive advanced non-small- cell lung cancer**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No potential equality issues were identified during the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No potential equality issues were identified.

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No potential equality issues were identified.

- | |
|--|
| 4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other |
|--|

groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
No potential equality issues were identified. Included under 'Other considerations' (section 3.28).

Approved by Associate Director (name): Helen Knight

Date: 27/03/2018

Final appraisal determination

(when an ACD issued)

Technology appraisals: Guidance development
Equality impact assessment for the single technology appraisal of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small- cell lung cancer

Issue date: August 2018

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

Consultation comments highlighted that people with ALK-positive NSCLC are often younger, fitter, and less likely to have a smoking history than other groups of people with lung cancer. This population may be disadvantaged because they are less likely to be diagnosed through traditional screening programmes, and are more likely to be misdiagnosed. This is not an equalities issue that can be addressed by the committee. The committee has recommended alectinib in this population.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Section 3.33 notes that no equality issues were identified.

Approved by Associate Director (name): Helen Knight

Date: 06/08/2018